MX9806265A - TABLETA QUE CONTIENE EL ANTIBIOTICO beta-LACTAMA Y PRODUCCION DE LA MISMA. - Google Patents

TABLETA QUE CONTIENE EL ANTIBIOTICO beta-LACTAMA Y PRODUCCION DE LA MISMA.

Info

Publication number
MX9806265A
MX9806265A MX9806265A MX9806265A MX9806265A MX 9806265 A MX9806265 A MX 9806265A MX 9806265 A MX9806265 A MX 9806265A MX 9806265 A MX9806265 A MX 9806265A MX 9806265 A MX9806265 A MX 9806265A
Authority
MX
Mexico
Prior art keywords
beta
lactam antibiotic
producing
tablets containing
same
Prior art date
Application number
MX9806265A
Other languages
English (en)
Spanish (es)
Inventor
Hisami Yamaguchi
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of MX9806265A publication Critical patent/MX9806265A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Seasonings (AREA)
MX9806265A 1996-02-29 1998-08-04 TABLETA QUE CONTIENE EL ANTIBIOTICO beta-LACTAMA Y PRODUCCION DE LA MISMA. MX9806265A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4274396 1996-02-29
JP32026496 1996-11-29

Publications (1)

Publication Number Publication Date
MX9806265A true MX9806265A (es) 1998-12-31

Family

ID=26382481

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9806265A MX9806265A (es) 1996-02-29 1998-08-04 TABLETA QUE CONTIENE EL ANTIBIOTICO beta-LACTAMA Y PRODUCCION DE LA MISMA.

Country Status (23)

Country Link
US (4) US6423341B1 (enExample)
EP (2) EP1166651B1 (enExample)
JP (1) JP3180350B2 (enExample)
KR (1) KR20040058360A (enExample)
CN (2) CN1136853C (enExample)
AR (1) AR006012A1 (enExample)
AT (2) ATE287218T1 (enExample)
AU (1) AU724946B2 (enExample)
BR (1) BR9707780A (enExample)
CA (1) CA2248179C (enExample)
DE (2) DE69732312T8 (enExample)
DK (2) DK0890359T3 (enExample)
EA (1) EA001089B1 (enExample)
ES (2) ES2173420T3 (enExample)
HU (1) HU227821B1 (enExample)
IL (1) IL125214A0 (enExample)
MX (1) MX9806265A (enExample)
NZ (2) NZ330864A (enExample)
PT (2) PT1166651E (enExample)
TR (1) TR199801680T2 (enExample)
TW (1) TW473393B (enExample)
WO (1) WO1997031639A1 (enExample)
ZA (1) ZA971584B (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6746105B2 (en) 1997-07-15 2004-06-08 Silverbrook Research Pty. Ltd. Thermally actuated ink jet printing mechanism having a series of thermal actuator units
US5948440A (en) * 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
CA2323680C (en) 1998-05-18 2007-05-22 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
CA2581111A1 (en) * 1998-07-28 2000-02-10 Takeda Pharmaceutical Company Limited Rapidly disintegrable solid preparation
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20070160675A1 (en) * 1998-11-02 2007-07-12 Elan Corporation, Plc Nanoparticulate and controlled release compositions comprising a cephalosporin
CZ302015B6 (cs) 1999-10-08 2010-09-08 Affinium Pharmaceuticals, Inc. Inhibitory Fab I
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
FR2814679B1 (fr) * 2000-09-29 2003-04-11 Cll Pharma Compositions pharmaceutiques dispersibles a base de cephalosporines, leur procede de preparation et leur utilisation
JP4387804B2 (ja) * 2001-04-06 2009-12-24 アフィニアム・ファーマシューティカルズ・インコーポレイテッド ＦａｂＩ阻害剤
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
TW200404550A (en) * 2002-07-08 2004-04-01 Sankyo Co Cepharospolin formulation for oral use
JP4526247B2 (ja) * 2002-07-08 2010-08-18 第一三共株式会社 経口用セファロスポリン製剤
JP2006500356A (ja) * 2002-08-13 2006-01-05 サンド・アクチエンゲゼルシヤフト セフジニル中間体
EP1575951B1 (en) 2002-12-06 2014-06-25 Debiopharm International SA Heterocyclic compounds, methods of making them and their use in therapy
JP4880448B2 (ja) * 2003-03-17 2012-02-22 アフィナム ファーマシューティカルズ，インコーポレーテッド 複数の抗生物質を含む組成物、及びそれを用いる方法
KR20050121209A (ko) * 2003-03-24 2005-12-26 에이씨에스 도브파 에스. 피. 에이. 7-[2-(2-아미노티아졸-4-일)-2-하이드록시이미노아세트아미도-3-비닐-3-세펨-4-카복실산(신 이성체)의 신규 결정 및이의 제조방법
KR20080083071A (ko) * 2003-08-08 2008-09-12 아지노모토 가부시키가이샤 나테글리니드 함유 제제
US20050059818A1 (en) * 2003-09-12 2005-03-17 Duerst Richard W. Polymorph of a pharmaceutical
US20050113355A1 (en) * 2003-09-12 2005-05-26 Duerst Richard W. Cefdinir pyridine salt
US20050059819A1 (en) * 2003-09-12 2005-03-17 Duerst Richard W. Cefdinir pyridine salt
JP2005162696A (ja) * 2003-12-04 2005-06-23 Nichiko Pharmaceutical Co Ltd 溶出性に優れたセフジトレンピボキシル製剤
US20050131079A1 (en) * 2003-12-10 2005-06-16 Pujara Chetan P. Cefdinir oral suspension
US20080139528A1 (en) * 2003-12-10 2008-06-12 Pujara Chetan P Cefdinir oral suspension
US20060211676A1 (en) * 2004-03-16 2006-09-21 Devalina Law Crystalline anhydrous cefdinir and crystalline cefdinir hydrates
US20060142563A1 (en) * 2004-03-16 2006-06-29 Devalina Law Crystalline anhydrous cefdinir and crystalline cefdinir hydrates
US20060142261A1 (en) * 2004-03-16 2006-06-29 Devalina Law Crystalline anhydrous cefdinir and crystalline cefdinir hydrates
US20060069079A1 (en) * 2004-09-27 2006-03-30 Sever Nancy E Stable amorphous cefdinir
JP2007536378A (ja) * 2004-05-10 2007-12-13 ルピン・リミテッド 生体利用性が強化されている新規セフィキシム医薬製剤
CN1767818A (zh) * 2004-05-31 2006-05-03 三亚药品株式会社 含β－内酰胺抗生素的分散片剂及其制备方法
KR101299399B1 (ko) * 2004-06-04 2013-08-22 아피늄 파마슈티컬스, 인크. 치료제, 및 그의 제조 및 사용 방법
US20060099253A1 (en) * 2004-10-20 2006-05-11 Wyeth Antibiotic product formulation
IL169678A (en) 2005-07-14 2010-11-30 Innova Sa Sweetener compositions
WO2007067416A2 (en) * 2005-12-05 2007-06-14 Affinium Pharmaceuticals, Inc. Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
US20070128268A1 (en) * 2005-12-07 2007-06-07 Herwig Jennewein Pharmaceutical compositions comprising an antibiotic
WO2007125541A1 (en) * 2006-05-01 2007-11-08 Lupin Limited Pharmaceutical compositions of cefdinir
EP2687533B1 (en) 2006-07-20 2017-07-19 Debiopharm International SA Acrylamide derivatives as FAB I inhibitors
JP5289975B2 (ja) * 2006-12-07 2013-09-11 第一三共株式会社 マンニトール又は乳糖を含有する固形製剤
WO2008072535A1 (ja) * 2006-12-07 2008-06-19 Daiichi Sankyo Company, Limited 低置換度ヒドロキシプロピルセルロースを含有する医薬組成物
JP5433235B2 (ja) * 2006-12-07 2014-03-05 第一三共株式会社 固形製剤の製造方法
US8263613B2 (en) * 2007-02-16 2012-09-11 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab I inhibitors
TR200909785A1 (tr) * 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
US8614315B2 (en) 2009-12-25 2013-12-24 Mahmut Bilgic Cefdinir and cefixime formulations and uses thereof
WO2011078830A1 (en) * 2009-12-25 2011-06-30 Bilgic Mahmut Rapidly dispersing effervescent formulation
TR200909786A1 (tr) 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Sefiksim içeren efervesan tablet ve granül formülasyonu.
TR201000686A1 (tr) * 2010-01-29 2011-08-22 B�Lg�� Mahmut Bakteriyel enfeksiyonların tedavisinde suda çözünebilir sefdinir ve klavulanik asit formülasyonları.@
TR201000687A1 (tr) * 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Aktif madde olarak sefiksim ve klavulanik asit içeren efervesan formülasyonlar
TR201001417A1 (tr) 2010-02-25 2011-09-21 Sanovel İlaç San. Ve Ti̇c. A. Ş. Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu
WO2011139249A2 (en) * 2010-05-04 2011-11-10 Mahmut Bilgic Pharmaceutical composition comprising cefdinir
EP2568959A2 (en) * 2010-05-14 2013-03-20 Mahmut Bilgic Formulations comprising a third generation cephalosporin and clavulanic acid
EA021874B1 (ru) * 2010-09-13 2015-09-30 ЛИМОНОВ, Виктор Львович Фармацевтическая композиция антимикробного действия для парентерального введения и способ ее получения
TR201009166A2 (tr) * 2010-11-05 2012-05-21 Bi̇lgi̇ç Mahmut Sefdinir içeren farmasötik bileşim için üretim yöntemi
TR201010212A2 (tr) * 2010-12-08 2012-06-21 Bi̇lgi̇ç Mahmut Sefdinir içeren katı oral dozaj formu.
CA2875916C (en) 2012-06-19 2017-04-25 Debiopharm International Sa Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
WO2014051532A1 (en) * 2012-09-28 2014-04-03 Bilgic Mahmut Pharmaceutical tablet formulations comprising cefdinir
LT2903457T (lt) * 2012-10-02 2018-03-26 Montero Gida Sanayi Ve Ticaret A.S. Mogrosido kompozicija ir jos gavimo būdas
EP2906203B1 (en) 2012-10-11 2018-01-03 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Effervescent cefdinir formulation
EP2815743A1 (en) 2013-06-21 2014-12-24 Sanovel Ilac Sanayi ve Ticaret A.S. Ceftibuten formulations
US20160242439A1 (en) 2014-04-04 2016-08-25 Douxmatok Ltd Method for producing sweetener compositions and sweetener compositions
US10207004B2 (en) 2014-04-04 2019-02-19 Douxmatok Ltd Method for producing sweetener compositions and sweetener compositions
US10231476B2 (en) 2014-04-04 2019-03-19 Douxmatok Ltd Sweetener compositions and foods, beverages, and consumable products made thereof
HUE052140T2 (hu) 2016-02-26 2021-04-28 Debiopharm Int Sa Diabéteszes lábfertõzések kezelésére szolgáló gyógyszer
FI3923914T3 (fi) 2019-02-14 2023-04-27 Debiopharm Int Sa Afabisiiniformulaatio, menetelmä sen valmistamiseksi
US12414958B2 (en) 2019-06-14 2025-09-16 Debiopharm International S.A. Medicament and use thereof for treating bacterial infections involving biofilm
CN115607514B (zh) * 2021-07-16 2023-12-12 广州白云山天心制药股份有限公司 一种含有头孢地尼颗粒的制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3098749A (en) * 1960-11-16 1963-07-23 Abbott Lab Sweetening agent and process of producing the same
US3336199A (en) * 1963-07-03 1967-08-15 Warner Lambert Pharmaceutical Tablet composition
DE2251250C3 (de) * 1972-10-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Verfahren zur Herstellung hochdosierter Antibiotica-Tabletten
US4039673A (en) * 1973-10-30 1977-08-02 Bayer Aktiengesellschaft Penicillins and cephalosporins and their production
JPS5438167B2 (enExample) * 1974-04-27 1979-11-19
US4248894A (en) * 1979-01-17 1981-02-03 Life Savers, Inc. Long-lasting flavored chewing gum containing non-sugar sweetener codried on chalk or other filler and method
US4384005A (en) * 1980-09-26 1983-05-17 General Foods Corporation Non-friable, readily-soluble, compressed tablets and process for preparing same
JPS57150361A (en) * 1981-03-10 1982-09-17 Ajinomoto Co Inc Granule of dipeptide sweetener
US4352821A (en) * 1981-07-21 1982-10-05 Shaklee Corporation Sweet tableting agent
DE3266580D1 (en) * 1981-12-02 1985-10-31 Beecham Group Plc Pharmaceutical formulation comprising beta-lactam antibiotics
JPS58198268A (ja) * 1982-05-14 1983-11-18 Ajinomoto Co Inc 甘味料顆粒又はキユ−ブの製造法
US4600579A (en) * 1983-06-07 1986-07-15 Mallinckrodt, Inc. N-acetyl-p-aminophenol compositions containing partially gelatinized starch and method for preparing same
US4752485A (en) * 1984-10-05 1988-06-21 Warner-Lambert Company Novel sweetener delivery systems
US4722845A (en) * 1986-12-23 1988-02-02 Warner-Lambert Company Stable cinnamon-flavored chewing gum composition
ES2061623T3 (es) * 1987-03-02 1994-12-16 Brocades Pharma Bv Procedimiento para la obtencion de una composicion farmaceutica y un granulado farmaceutico.
US4915948A (en) * 1987-08-31 1990-04-10 Warner-Lambert Company Tablets having improved bioadhesion to mucous membranes
JPH01206969A (ja) * 1987-10-30 1989-08-21 Takeda Chem Ind Ltd 甘味料顆粒の製造法
JPH01149728A (ja) * 1987-12-04 1989-06-12 Fujisawa Pharmaceut Co Ltd 抗潰瘍剤
FR2634355B1 (fr) * 1988-07-25 1990-09-14 Beghin Say Sa Nouveau produit edulcorant alimentaire a base de saccharose et d'edulcorant intense et son procede de preparation
US5085876A (en) * 1988-11-16 1992-02-04 The Nutrasweet Company Fast dissolving sweetening agent including caramel
US5114929A (en) * 1989-03-21 1992-05-19 Beecham Group P.L.C. Pharmaceutical formulation
FR2669221B1 (fr) * 1990-11-15 1993-01-15 Rhone Poulenc Sante Procede de preparation par compression directe de comprimes de derives de l'acide cephalosporanique.
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
DE69331839T2 (de) * 1992-01-29 2002-12-12 Takeda Chemical Industries, Ltd. Schnellösliche Tablette und ihre Herstellung
ES2059260B1 (es) * 1992-10-06 1995-04-16 Espanola Prod Quimicos Procedimiento de preparacion de comprimidos conteniendo diclofenaco; dispersables en agua.
JP3063438B2 (ja) * 1992-12-24 2000-07-12 田辺製薬株式会社 ドパミン誘導体含有経口投与用製剤
EP0711554A4 (en) * 1993-07-28 1997-07-23 Nippon Shinyaku Co Ltd ANTIDEPRESSANT
JP2994956B2 (ja) * 1994-05-31 1999-12-27 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロース、その組成物およびその錠剤
DE4418957A1 (de) * 1994-05-31 1995-12-07 Merck Patent Gmbh Cefixim-Zubereitung
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
FR2722984B1 (fr) * 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.

Also Published As

Publication number Publication date
US20070134325A1 (en) 2007-06-14
US20030129227A1 (en) 2003-07-10
HUP9901877A3 (en) 2000-04-28
BR9707780A (pt) 1999-07-27
DE69712332T2 (de) 2002-10-02
ES2231369T3 (es) 2005-05-16
DK1166651T3 (da) 2005-05-30
TR199801680T2 (xx) 1999-02-22
IL125214A0 (en) 1999-03-12
PT890359E (pt) 2003-03-31
TW473393B (en) 2002-01-21
CN1136853C (zh) 2004-02-04
CA2248179A1 (en) 1997-09-04
JP3180350B2 (ja) 2001-06-25
HU227821B1 (en) 2012-03-28
DE69712332D1 (de) 2002-06-06
AU724946B2 (en) 2000-10-05
EA001089B1 (ru) 2000-10-30
HUP9901877A1 (hu) 1999-12-28
HK1015684A1 (en) 1999-10-22
DE69732312T8 (de) 2006-07-27
NZ512609A (en) 2003-03-28
AR006012A1 (es) 1999-07-21
KR20040058360A (ko) 2004-07-03
AU1734797A (en) 1997-09-16
CN1409995A (zh) 2003-04-16
NZ330864A (en) 2001-07-27
ZA971584B (en) 1997-09-10
US20020192281A1 (en) 2002-12-19
EP0890359B1 (en) 2002-05-02
CA2248179C (en) 2007-09-18
EP0890359A1 (en) 1999-01-13
PT1166651E (pt) 2005-04-29
DE69732312T2 (de) 2006-04-06
US6423341B1 (en) 2002-07-23
EA199800775A1 (ru) 1999-02-25
ATE287218T1 (de) 2005-02-15
EP1166651B1 (en) 2005-01-19
DE69732312D1 (de) 2005-02-24
CN1212626A (zh) 1999-03-31
EP0890359A4 (enExample) 1999-01-13
ES2173420T3 (es) 2002-10-16
DK0890359T3 (da) 2002-07-01
EP1166651A1 (en) 2002-01-02
ATE216887T1 (de) 2002-05-15
WO1997031639A1 (en) 1997-09-04
US20020051816A1 (en) 2002-05-02

Similar Documents

Publication Publication Date Title
MX9806265A (es) TABLETA QUE CONTIENE EL ANTIBIOTICO beta-LACTAMA Y PRODUCCION DE LA MISMA.
HUT51269A (en) Process for producing benzimidazole derivatives and pharmaceutical compositions comprising same
AU1729397A (en) Process to prepare soluble delivery systems using volatile salts
TW352384B (en) Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
NO954996D0 (no) Anvendelse av nona- og dekapeptider for fremstilling av et legemiddel for behandling av AIDS
GR3022510T3 (en) Lyospheres comprising gonadotropin
AU1252088A (en) Pharmaceutical composition, pharmaceutical granulate and process for their preparation
JO1969B1 (en) Granulation process for the preparation of rapidly dissolving and dissolving compounds containing a high amount of the drug
MY137768A (en) Rapidly disintegrating methylcellulose tablets
IL86551A0 (en) (1h-azol-1-ylmethyl)substituted benzotriazole derivatives,their preparation and pharmaceutical compositions containing them
HUT55403A (en) Process for producing modified gangliosides and their functional derivatives, as well as pharmaceutical compositions comprising such active ingredient
AU2705588A (en) New ciclosporin crystal form, processes for its production, pharmaceutical compositions containing it and its use.
GB9624563D0 (en) Product
ZA927205B (en) Acylals of imidazole-5-carboxylic acid derivatives, process for their preparation and their use.
AU6788687A (en) A pharmaceutical which can be administered nasally, a process for its preparation, and its use
IL93988A0 (en) Substituted 1,8-naphthyridines,their preparation and medicaments comprising them
EP0427124A3 (en) Antacid tablets
ES8600758A1 (es) Procedimiento para preparar derivados de1,3-dioxolanilo
EP0399435A3 (en) Crosslinked carboxymethylguar tablet disintegrant
MD457G2 (ro) Derivaţi noi de naftiridină, procedeu de preparare a lor, compoziţii farmaceutice care le conţin, utilizarea lor ca medicamente de antireproducere
AU631407B2 (en) Magnesium folates, process for their preparation and pharmaceutical compositions
ZA91901B (en) Side-chain homologous vitamin d derivatives,process for their production,pharmaceutical preparations containing these derivatives and their use as pharmaceutical agents
AU578125B2 (en) Pyrazine diazohydroxide compounds
JO1531B1 (en) New near-compounds
NZ304823A (en) Beta carboline derivatives and medicaments